source
- Merck and Moderna release early phase 3 melanoma vaccine data showing primary endpoint success but weaker secondary resultsMerck and Moderna disclosed phase 3 data for their melanoma vaccine INTerpath-001 ahead of schedule after an embargo breach. The trial met its primary endpoint of recurrence‑free survival, with re…
- Hologic acquires Spain’s Reveal Genomics to expand breast cancer genomic testingHologic, a medical‑technology company, announced it will acquire precision‑oncology firm Reveal Genomics, based in Spain. Reveal Genomics develops advanced genomic diagnostic tests, notably the HE…